一品红：控股股东拟将所持美国Arthrosi公司9.07%股权无偿给予公司

Core Viewpoint - The company received a commitment from its controlling shareholder to support its development, particularly in relation to the acquisition of Arthrosi and the innovative gout drug AR882 in the Greater China market [1] Group 1 - The controlling shareholder, Guangrun Group, plans to transfer 9.07% of its stake in the U.S. company Arthrosi, held through its subsidiary Guangrun Health, to the company without any conditions or compensation [1] - This transfer is based on strong confidence in the acquisition of Arthrosi and the market potential of the innovative drug AR882 [1]